Session » Pediatric Rheumatology – Clinical and Therapeutic Aspects I: Autoinflammatory Diseases

Date: Monday, November 6, 2017

Time: 4:30PM-6:00PM

Meeting: 2017 ACR/ARHP Annual Meeting

4:30PM-6:00PM: Abstract Number: 1892

A20 Haploinsufficiency: Clinical Phenotypes and Disease Course of Patients with This Newly Recognized Autoinflammatory Disease

4:30PM-6:00PM: Abstract Number: 1894

Genetic Phenotypes Impacting Efficacy and Safety of Canakinumab in Patients with Colchicine-Resistant FMF, TRAPS and Hids/Mkd: Results from Cluster Study

4:30PM-6:00PM: Abstract Number: 1896

IL-18 As a Diagnostic Biomarker, Differentiating Systemic JIA from Acute Leukaemia, Severe Bacterial Infections and Other Auto-Immune Disorders

4:30PM-6:00PM: Abstract Number: 1893

Pharmacokinetics (PK), Pharmacodynamics (PD), and Proposed Dosing of Oral Janus Kinase (JAK)1 and JAK2 Inhibitor Baricitinib in Patients with IFN-Mediated Autoinflammatory Diseases (AIDs)

4:30PM-6:00PM: Abstract Number: 1895

Serum Interleukin 18 As a Biomarker for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome and Use of Recombinant Human IL-18 BP in a Patient with Refractory Disease

4:30PM-6:00PM: Abstract Number: 1897

the Ferritin to ESR Ratio: A Simple Measure to Distinguish Macrophage Activation Syndrome from Systemic Arthritis Flare

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].